Clinical Trial Update: Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating trastuzumab deruxtecan for HER2-positive newly diagnosed or recurrent osteosarcoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Osteosarcoma, Recurrent Osteosarcoma | Phase 2 | Status: SUSPENDED